Fuso Pharmaceutical Industries (TSE:4538) EBIT: 円1,248 Mil (TTM As of Mar. 2026)


TSE:4538 Fuso Pharmaceutical Industries Ltd TSE:4538
51 GF Score
Price 円2,071.00
GF Value 円2,540.99
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Fuso Pharmaceutical Industries EBIT?

Fuso Pharmaceutical Industries TSE:4538 +0.34% 51 EBIT is 円1,248 Mil as of Mar. 2026. GuruFocus rates TSE:4538 with a GF Score™ of 51/100 and a GF Value™ of 円2,540.99 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Fuso Pharmaceutical Industries's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was 円0 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was 円1,248 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Fuso Pharmaceutical Industries's annualized ROC % for the quarter that ended in Mar. 2026 was 0.00%. Fuso Pharmaceutical Industries's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 0.00%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Fuso Pharmaceutical Industries's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.02%.


Fuso Pharmaceutical Industries  (TSE:4538) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Fuso Pharmaceutical Industries's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=0 * ( 1 - 0% )/( (76251 + 77043)/ 2 )
=0/76647
=0.00 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Fuso Pharmaceutical Industries's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0/( ( (22620 + max(24231, 0)) + (22186 + max(27410, 0)) )/ 2 )
=0/( ( 46851 + 49596 )/ 2 )
=0/48223.5
=0.00 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(22836 + 14846 + 9844) - (4544 + 0 + 18751)
=24231

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(26897 + 15682 + 9911) - (8434 + 0 + 16646)
=27410

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Fuso Pharmaceutical Industries's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1248/41296.233
=3.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fuso Pharmaceutical Industries EBIT Related Terms


Fuso Pharmaceutical Industries EBIT Historical Data

* Premium members only.

The historical data trend for Fuso Pharmaceutical Industries's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fuso Pharmaceutical Industries EBIT Chart

Fuso Pharmaceutical Industries Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,087.00 2,370.00 1,938.00 -4,809.00 2,766.00

Fuso Pharmaceutical Industries Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,269.00 0.00 717.00 531.00 0.00

TSE:4538 vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Fuso Pharmaceutical Industries's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fuso Pharmaceutical Industries EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Fuso Pharmaceutical Industries's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Fuso Pharmaceutical Industries's EV-to-EBIT falls into.


TSE:4538
51GF Score
Fuso Pharmaceutical Industries Ltd TSE:4538
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fuso Pharmaceutical Industries EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円1,248 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of 円1,248 Mil mean?
Fuso Pharmaceutical Industries (TSE:4538) has a EBIT of 円1,248 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Fuso Pharmaceutical Industries.
Is Fuso Pharmaceutical Industries' EBIT too high?
Fuso Pharmaceutical Industries' current EBIT is 円1,248 Mil. Overall, Fuso Pharmaceutical Industries has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fuso Pharmaceutical Industries' EBIT compare to ZTS?
Fuso Pharmaceutical Industries' EBIT of 円1,248 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Fuso Pharmaceutical Industries. Fuso Pharmaceutical Industries's current EBIT is 円1,248 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuso Pharmaceutical Industries stock overvalued right now?
Based on GuruFocus' analysis, Fuso Pharmaceutical Industries (TSE:4538) is currently considered Modestly Undervalued. The stock's GF Value™ is 円2,540.99, compared to a current price of 円2,071.00 — trading 18.5% below its estimated fair value. The current EBIT is 円1,248 Mil. Fuso Pharmaceutical Industries' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Fuso Pharmaceutical Industries (TSE:4538), the current EBIT is 円1,248 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fuso Pharmaceutical Industries (TSE:4538) Overvalued in 2026?

Based on GuruFocus' analysis, Fuso Pharmaceutical Industries stock appears to be undervalued. The current stock price of 円2,071.00 is trading 18.5% below its estimated GF Value™ of 円2,540.99. GuruFocus considers Fuso Pharmaceutical Industries to be Modestly Undervalued.

Key valuation signals for TSE:4538:

  • EBIT: 円1,248 Mil
  • GF Value™: 円2,540.99 vs. price of 円2,071.00 (18.5% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the TSE:4538 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fuso Pharmaceutical Industries Business Description

Address No. 10, No. 7-chome Doshomachi, Chuo-ku, OsaKa, JPN, 541-0045
Fuso Pharmaceutical Industries Ltd. is engaged in the manufacture and sale of pharmaceuticals and medical equipment. The company's main products are transfusion fluid and artificial kidney dialysis fluid. Company also includes real estate segment.
51GF Score

Get the complete analysis for TSE:4538

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円2,071.00
Price
円2,540.99
GF Value